163 related articles for article (PubMed ID: 38521834)
21. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
23. Schwannomatosis: the overlooked neurofibromatosis?
Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
[TBL] [Abstract][Full Text] [Related]
24. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.
Farschtschi SC; Kluwe L; Schön G; Friedrich RE; Matschke J; Glatzel M; Weis J; Hagel C; Mautner VF
Brain Pathol; 2020 Mar; 30(2):386-391. PubMed ID: 31424590
[TBL] [Abstract][Full Text] [Related]
25. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
26. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis.
Halliday D; Emmanouil B; Evans DGR
Clin Genet; 2023 May; 103(5):540-552. PubMed ID: 36762955
[TBL] [Abstract][Full Text] [Related]
27. What to know about schwannomatosis: a literature review.
Schraepen C; Donkersloot P; Duyvendak W; Plazier M; Put E; Roosen G; Vanvolsem S; Wissels M; Bamps S
Br J Neurosurg; 2022 Apr; 36(2):171-174. PubMed ID: 33263426
[TBL] [Abstract][Full Text] [Related]
28. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
29. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
Hadfield KD; Smith MJ; Urquhart JE; Wallace AJ; Bowers NL; King AT; Rutherford SA; Trump D; Newman WG; Evans DG
Oncogene; 2010 Nov; 29(47):6216-21. PubMed ID: 20729918
[TBL] [Abstract][Full Text] [Related]
30. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
31. Identifying challenges in neurofibromatosis: a modified Delphi procedure.
Dhaenens BAE; Ferner RE; Bakker A; Nievo M; Evans DG; Wolkenstein P; Potratz C; Plotkin SR; Heimann G; Legius E; Oostenbrink R
Eur J Hum Genet; 2021 Nov; 29(11):1625-1633. PubMed ID: 33903738
[TBL] [Abstract][Full Text] [Related]
32. Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization.
Gugel I; Grimm F; Tatagiba M; Schuhmann MU; Zipfel J
J Neurooncol; 2022 Sep; 159(2):271-279. PubMed ID: 35771312
[TBL] [Abstract][Full Text] [Related]
33. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
34. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
Da JLW; Merker VL; Jordan JT; Ly KI; Muzikansky A; Parsons M; Wolters PL; Xu L; Styren S; Brown MT; Plotkin SR
Contemp Clin Trials; 2022 Oct; 121():106900. PubMed ID: 36038003
[TBL] [Abstract][Full Text] [Related]
35. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
[TBL] [Abstract][Full Text] [Related]
36. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
[TBL] [Abstract][Full Text] [Related]
38. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
39. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Vranceanu AM; Merker VL; Plotkin SR; Park ER
J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
[TBL] [Abstract][Full Text] [Related]
40. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
Kehrer-Sawatzki H; Farschtschi S; Mautner VF; Cooper DN
Hum Genet; 2017 Feb; 136(2):129-148. PubMed ID: 27921248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
